Shiftless Corporations Renounce America
Early last week, the drug firm Mylan stomped on the Stars and Stripes as it ditched America for the Netherlands. Then, on Friday, the drug company AbbVie similarly renounced America. For 30 pieces of silver, it will become Irish.
Medical device maker Medtronic deserted America for Ireland last month. The pharmacy chain Walgreens recently announced it may be next. It plans to dump the land of the free for the bows and scrapes of royal subjects.
Walgreens is willing to prostrate itself before Queen Elizabeth because the British corporate tax rate is lower. Anything for money, right AbbVie? These firms will still park their assets and staff and sales in America. They just won’t pay taxes on foreign income to the country that nurtured them, protected them from patent violators and unfair competitors, and provided them with educated workers, federally-sponsored research and development, and myriad other public services. Now, they can freeload instead. As a result, their U.S. competitors, as well as hardworking Americans, will pay more to cover the shirkers’ share.
This foreign address squatting is formally called inversion. A large American corporation seeking to evade its tax responsibilities hooks up with company in a low tax country. It makes sure the foreign firm ends up with at least 20 percent of the combined company’s stock, so the American corporation can legally change its address. It’s called inversion because the big buyer takes the smaller subsumed entity’s address instead of the other way around. Dozens of corporations have done it in the past couple of years.
At least one former chief executive officer condemned the practice. That would be Bill George, who wrote in the New York Times about an inversion proposed by Pfizer:
“Is the role of leading large pharmaceutical companies to discover lifesaving drugs or to make money for shareholders through financial engineering? Does anyone believe pharmaceutical companies can create long-term shareholder value by chasing lower tax venues and cutting research and development spending?”
But a month later when George’s alma mater Medtronic launched the same tax dodge maneuver, well, then it was a completely different story. For Medtronic, George said, tax evasion was hunky-dory:
“The only reason they’re doing the inversion is to free up the cash overseas. . . That money today can’t be put to good use right now.” That, of course, isn’t true. It could be put to good use immediately if Medtronic paid the federal income tax the company owes on it.
Medtronic has about $14 billion squirrelled away offshore. It would have to pay between $3.5 and $4.2 billion in federal taxes to bring the money back for use at its headquarters in Minnesota. That’s the difference between the official U.S. tax rate of 35 percent and the 5 to 10 percent rate Medtronic already has paid to other countries where the money was made. Instead of paying its American taxes, Medtronic will spend $43 billion to buy an Irish firm.
When George was Medtronic CEO, he worked to lower the firm’s tax rate. And he succeeded masterfully. Like the vast majority of U.S. companies, Medtronic doesn’t pay anywhere near the official 35 percent. It pays 18 percent. That’s still too much, according to George, who told the New York Times: “The taxes are simply too high in this country.”
Too high for AbbVie as well. It paid 22.6 percent last year and projects that renouncing America will lower its rate to 13 percent by 2016.
George called for another corporate tax holiday during which multi-nationals could repatriate their foreign earnings without paying all of the taxes owed. Great for them, of course, but not for the federal budget deficit. And, frankly, unfair to working Americans never granted tax holidays.